Omniab, Inc. · NASDAQ:OABI
Omniab — Q1 2024 Earnings Presentation
16 slides from Omniab's earnings presentation, May 9, 2024
Slide 1: Q1 2024 Financial Results & Business Update
1 Q1 2024 Financial Results & Business Update Nasdaq: OABI May 9, 2024
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected operating expense and cash
Slide 3: Introduction
Omni > Introduction : Matt Foehr
Slide 4: Q1 2024 Highlights
4 Q1 2024 Highlights POSITIONING THE BUSINESS FOR FUTURE GROWTH Continuing to grow and diversify our partnership base An expanded presence is creating greater visibility for our technology with target audience Newest innovations and workflows driving value for stakeholders
Slide 5: Active Partners
5 Active Partners Q1 2024: 80 ACTIVE PARTNERS Number of Active Partners 80 • 3 new platform license agreements were signed in the first quarter 60 ‒ New platform license agreements with a stealth Boston-based venture- backed start-up, ImmunoBiochem Corporation, and the University of Georgia 40 • Nea
Slide 6: Active Programs
6 Active Programs GROWTH AND PROGRESSION CONTINUES Number of Active Programs 327 Active Programs as of 3/31/2024 300 Phase 3: 1 Phase 2: 3 Registration: 1 • Number of Active Programs increased Phase 1: 23 Approved: 3 to 327, net of attrition Preclinical: 18 200 • 3 programs successfully transitioned
Slide 7: Active Clinical Programs and Approved Products
7 Active Clinical Programs and Approved Products Number of Active Clinical Programs and Approved Products 40 • 31 active clinical programs as of 3/31/2024 ‒ RO7515629/RG6353(1), a Phase 1 antibody program in oncology removed following a "portfolio shaping" initiative at Roche(2) 30 • Based on dialog
Slide 8: Select Partner Updates
8 Select Partner Updates RECENT DEVELOPMENTS AND UPCOMING KEY EVENTS Batoclimab IMVT-1402 M9140 Acasunlimab FcRn FcRn CEACAM-5 ADC PD-L1 x 4-1BB Immunovant reported that global Immunovant announced plans to AACR presentation on M9140, a Genmab expects acasunlimab Phase 3 clinical trials of batoclima
Slide 9: Selected Clinical Presentations at ASCO
9 Selected Clinical Presentations at ASCO THE ASCO ANNUAL MEETING IS TAKING PLACE MAY 31ST TO JUNE 4TH Acasunlimab Zimberelimab PD-L1 x 4-1BB PD-1 Acasunlimab (duobody-PD-L1x4-1BB) alone or in combination with A Phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab pembrolizumab in patients w
Slide 10: Upcoming Scientific Presentations
10 Upcoming Scientific Presentations INCREASING THE VISIBILITY OF OUR TECHNOLOGY PLATFORM May 15th June 4th Boston London OmnidAb : Transgenic Chickens Producing Human Heavy Chain-Only Antibodies Demonstrate Robust Deep Screening in Harmony with Artificial Immune Repertoires and High-Affinity Bindin
Slide 11: Financial Updates
11 Financial Updates Kurt Gustafson
Slide 12: Q1 2024 vs. Q1 2023 Financial Results
12 Q1 2024 vs. Q1 2023 Financial Results (Millions, except per share data) Q1 2024 Q1 2023 Variance License and milestone revenue $ 0.7 $ 12.6 ($ 11.9) Service revenue 2.8 4.0 (1.2) Royalty revenue 0.3 0.3 0.0 Total revenues 3.8 16.9 (13.1) Research & development 14.6 13.8 0.8 The Company expects op
Slide 13: Balance Sheet
13 Balance Sheet (Millions) March 31, December 31, 2024 2023 ASSETS We expect cash use in 2024 to be relatively Current assets: similar to the cash use in 2023, excluding the Cash & investments $ 69.0 $ 87.0 $35M TECVAYLI® milestone that was received Accounts receivable, net 4.0 3.8 in Q1 2023 Other
Slide 14: Q&A
Omni Q&A
Slide 15: Omni >
Omni >
Slide 16: Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline
Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 3/31/2024 16 Partner Program Source Animal Therapy Area Target Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD-1 Sugemalimab OmniRat Oncology PD-L1 Teclistamab OmniRat Oncology BCMA x CD3 Batoc